Exane BNP Paribas initiated coverage of Xylem with a rating of Outperform and set a new price target of $150.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $148.00 | Overweight | Analyst |
| 12/12/2024 | Outperform → Peer Perform | Wolfe Research | |
| 12/9/2024 | $135.00 → $148.00 | Neutral → Buy | Citigroup |
| 9/3/2024 | $138.00 | Buy → Hold | TD Cowen |
| 8/13/2024 | $165.00 | Buy | UBS |
| 3/12/2024 | $150.00 | Outperform | Exane BNP Paribas |
| 1/4/2024 | Underperform → Mkt Perform | Raymond James | |
| 12/13/2023 | $127.00 | Outperform | Wolfe Research |
4 - Xylem Inc. (0001524472) (Issuer)
4 - Xylem Inc. (0001524472) (Issuer)
4 - Xylem Inc. (0001524472) (Issuer)
Analyst initiated coverage of Xylem with a rating of Overweight and set a new price target of $148.00
Wolfe Research downgraded Xylem from Outperform to Peer Perform
Citigroup upgraded Xylem from Neutral to Buy and set a new price target of $148.00 from $135.00 previously